BiotechTube
SpineX

SpineX

Los Angeles, United States· Est.
spinex.co
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

SpineX is a private, clinical-stage medical device company pioneering non-invasive spinal cord neuromodulation. Its two core investigational devices, SCONE™ for neurogenic bladder and SCiP™ for cerebral palsy, have both received FDA Breakthrough Device Designation, highlighting their potential to address significant unmet needs. The company is actively recruiting for a global SCONE™ clinical trial and anticipates initiating a pivotal trial for SCiP™ in 2024, targeting a combined market opportunity exceeding $15 billion.

UrologyNeurologyPediatrics

Technology Platform

Non-invasive transcutaneous spinal cord neuromodulation using surface electrode pads to deliver electrical stimulation, aiming to correct neurological deficits and restore organ function.

Opportunities

The combined market for neurogenic bladder and cerebral palsy treatments is estimated at over $15B, representing a vast unmet need.
FDA Breakthrough Device Designation for both programs can accelerate regulatory pathways and attract partnership interest.
The non-invasive platform could expand into other neurological indications characterized by spinal cord circuit dysfunction.

Risk Factors

Clinical trials may fail to demonstrate sufficient safety or efficacy for regulatory approval.
Securing insurance reimbursement for a novel, non-invasive neuromodulation therapy is a significant commercial hurdle.
The company faces execution risk in managing pivotal trials and the transition to commercialization as a pre-revenue entity.

Competitive Landscape

For neurogenic bladder, competitors include pharmaceutical therapies, invasive botox injections, and surgically implanted sacral neuromodulation devices (e.g., Medtronic's InterStim™). For cerebral palsy, standard care includes physical therapy, orthotics, and invasive surgeries. SpineX's non-invasive transcutaneous approach appears unique, particularly for CP, as indicated by its Breakthrough Designation.

More companies in Neuroscience & CNS →More companies in United States →